Amitriptyline (Elavil)

Category:

  • Miscellaneous

Description:

  • Tricyclic antidepressant, anxiolytic, antineurolgic

Indications:

  • Depression

  • Chronic pain (chronic tension headache, migraine, diabetic neuropathy, cancer pain, postherpetic neuralgia)

Contraindications:

  • Acute recovery phase of myocardial infarction

  • Concurrent use of monoamine oxidase inhibitors

Precautions:

  • Pregnancy category D; excreted into breast milk; effect on nursing infant unknown

  • Suicidal patients, convulsive disorders, prostatic hypertrophy, psychiatric disease, sever depression, increased intra-ocular pressure, narrow-angle glaucoma, urinary retention, hepatic/renal disease, hyperthyroidism, elderly, abrupt discontinuation

Adverse Reactions (Side Effects):

  • CNS: anxiety, confusion, dizziness, drowsiness, exra-pyridimal symptoms, insomnia, memory impairment, nervousness, nightmares, panic, stimulation, tremors, weakness

  • CV: dysrhythmias, hypertension, orthostatic hypotension, palpitations, syncope, tachycardia

  • EENT: blurred vision, mydriasis, nasal congestion, ophthalmoplegia, tinnitis

  • GI: constipation, cramps, diarrhea, dry mouth, epigastric distress, hepatitis, increased appetite, jaundice, nausea, paralytic ileus, stomatitis, vomiting, weight gain

  • HEME: agranulocytosis, eosinophilia, leukopenia, thrombocytopenia

  • GU: urinary retention

  • SKIN: photosensitivity, pruritis, rash, sweating, urticaria  

Dosage:

Administered orally (tablet) and intramuscularly (NEVER intravenously!)

  • Adult dose: 

    • PO 50-100mg at bedtime, 

    • may increase to 200mg daily, not to exceed 300mg daily (chronic pain doses usually at lower end of range)

    • IM (do not administer IV) 20-30mg four times daily, or 80-120mg at bedtime

  • Adolescent/geriatric: 

    • PO 30mg daily in divided doses

    • may be increase to 150mg daily

  • Child dose:   

    • chronic pain management: 

      • PO 0.1 mg/kg/day in 3 divided doses initially

      • advance as tolerated over 2-3 weeks to 0.5-2 mg/kg at bedtime

    • depression: 

      • PO 1 mg/kg/day in 3 divided doses initially

      • increases to 1.5 mg/kg/day

Drug interactions: 

Numerous, most significantly:

  • MAOI’s: (Monamine oxidase inhibitors)

    • excessive sympathetic response

    • mania

    • hyperpyrexia

  • Epinephrine, norepinephrine

    • enhanced pressor response

  • Guanethidine, guanadrel: 

    • inhibited antihypertensive response

  • Ethanol: 

    • additive impairment of motor skills

 

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site